Trials / Unknown
UnknownNCT05277792
Dosage of Tacrolimus Metabolites in Blood and Bile for Prediction of Its Side Effects in Liver Transplant Recipients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (estimated)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if concentration of tacrolimus metabolites is increased in patients presenting tacrolimus (TAC) side effects.
Detailed description
The study will evaluate whether the blood concentration of TAC metabolites (13-O-desmethyl-tacrolimus, 15-O-desmethyl-tacrolimus and 31-O-desmethyl-tacrolimus), measured between Day1 and Day5 of its introduction, is increased in patients with TAC toxicity. A blood test will be performed daily from Day1 to Day5 for the measurement of TAC concentration and TAC metabolites concentration.
Conditions
Timeline
- Start date
- 2022-05-08
- Primary completion
- 2024-06-08
- Completion
- 2024-06-08
- First posted
- 2022-03-14
- Last updated
- 2023-07-28
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05277792. Inclusion in this directory is not an endorsement.